Trial Tentatively Backs DOACs After TAVR

Published Date: 21 Sep 2026

HALT reduced without increase in safety events compared with aspirin

Read Full News

Latest News

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Tips on Optimizing HS Biologics, Combinations, and Surgery

Tips on Optimizing HS Biologics, Combinations, and Surgery

Conference Preview: Fall Clinical Dermatology Conference 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Patient Perspective on Topical Steroid Withdrawal, With Briana Banos Briana Banos

Topical steroid withdrawal advocate Briana Banos urged clinicians to stay curious and treat patients as experts on their own bodies.

Todays Updates

Q3 2026 Recap: Psychiatry News and Updates

Q3 2026 Recap: Psychiatry News and Updates

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Todays Updates

Q3 2026 Recap: Psychiatry News and Updates

Q3 2026 Recap: Psychiatry News and Updates

CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease Louie Pasculli

New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Latest News

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Tips on Optimizing HS Biologics, Combinations, and Surgery

Conference Preview: Fall Clinical Dermatology Conference 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Topical steroid withdrawal advocate Briana Banos urged clinicians to stay curious and treat patients as experts on their own bodies.

News All Time

What the FDA's Approval of Ameluz PDT Means for Skin Cancer Neal Bhatia, MD

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

EADV Congress 2026: Day 1 Recap — 6 Headlines to Know Victoria Johnson

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

FDA News Recap: Novel Drug Approvals in Q3 2026

FDA News Recap: Novel Drug Approvals in Q3 2026

NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates

NB-UVB Plus Upadacitinib Yields Higher Vitiligo Repigmentation Rates

EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis

EADV 2026: Tilrekimig Achieves EASI-75 Across All Doses in Atopic Dermatitis

Nail Detachment 4 Times More Common With GLP-1 Use

Nail Detachment 4 Times More Common With GLP-1 Use

Key Lessons in Leadership as a Clinician, With Kristina Duffin, MD Kristina Duffin, MD

Kristina Duffin, MD, MS, shares lessons from her LEADderm leadership session, including how to define which problems are truly yours to solve.

CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU Tim Smith

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis Tim Smith

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients Tim Smith

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

How Failure Is the Stepping Stone to Success, With Lisa Swanson, MD Lisa A. Swanson, MD

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Recommended News For You

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

Cancer research in the US is world class. With the government pulling out, its future is uncertain

Recommended Articles For You

Oncology Treatment: Innovations, Education, and Clinical Practice Insights 

Molecular Mechanisms of Tumor Extracellular-Matrix Stiffness Sensing 

Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy 

Breast Cancer Recovery: Fashion, Function, and Healing Beyond Scars 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For MDS-Related Anemia, Telomerase Inhibitor Approved.

2.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

3.

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.

4.

Treating Depression: Crucial for Recovery From Fibromyalgia

5.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

1.

Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights

2.

Immune Regulation of Blood Cell Development

3.

Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health

4.

Transformative Frameworks in Oncology for Better Care

5.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

1.

International Conference on Oncology, Cancer Prevention and Public Health

2.

International Conference on Cancer Nursing and Rehabilitation Strategies

3.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

4.

International Conference on Innovations in Critical Care for Oncology and Cardiology

5.

International Symposium on Oncology, Cardiology and Critical Care Innovations

1.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

2.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

3.

Understanding the causes of anemia in adults beyond nutritional deficiencies

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

5.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot